SLC22A2 and brain neoplasm: Having demonstrated suitability of [18F]FPIA for imaging brain tumor lesions, we examined whether tumor proliferation and the expression of lipid metabolism and transport proteins (CPT1, SLC22A2, SLC22A5, and SLC25A20), along with etomoxir treatment could relate to radiotracer uptake in HSJD-GBM-001 and U87 tumors.